Cell Transplantation· 2016Q1· Derleme
Mesenkimal Kök Hücrelerle Klinik Denemeler: Bir Güncelleme
Clinical Trials with Mesenchymal Stem Cells: An Update
- 1.450atıf
- Q1SCImago
- 2016yıl
Kısa özet
Rejeneratif ve farklılaşma yetenekleri nedeniyle mezankimal kök hücreler (MKH), hücre bazlı tedavilerde giderek daha fazla kullanılmaktadır; ABD NIH veritabanında 493 MKH bazlı klinik deneme kayıtlıdır.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- MKH'ler rejeneratif özelliklere sahiptir ve osteoblastlara, kondrositlere ve adipositlere farklılaşabilir.
- Heterojen izolasyon prosedürleri, ISCT'yi benzersiz MKH popülasyonlarını belirlemek için kriterler oluşturmaya yöneltmiştir.
- Kemik iliği ve diğer dokulardan elde edilen nonklonal stromal kültürler, MKH bazlı tedaviler için kaynak olarak kullanılmaktadır.
- ABD Ulusal Sağlık Enstitüleri ile toplam 493 MKH bazlı klinik deneme kayıtlıdır.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
In the last year, the promising features of mesenchymal stem cells (MSCs), including their regenerative properties and ability to differentiate into diverse cell lineages, have generated great interest among researchers whose work has offered intriguing perspectives on cell-based therapies for various diseases. Currently the most commonly used adult stem cells in regenerative medicine, MSCs, can be isolated from several tissues, exhibit a strong capacity for replication in vitro, and can differentiate into osteoblasts, chondrocytes, and adipocytes. However, heterogeneous procedures for isolating and cultivating MSCs among laboratories have prompted the International Society for Cellular Therapy (ISCT) to issue criteria for identifying unique populations of these cells. Consequently, the isolation of MSCs according to ISCT criteria has produced heterogeneous, nonclonal cultures of stromal cells containing stem cells with different multipotent properties, committed progenitors, and differentiated cells. Though the nature and functions of MSCs remain unclear, nonclonal stromal cultures obtained from bone marrow and other tissues currently serve as sources of putative MSCs for therapeutic purposes, and several findings underscore their effectiveness in treating different diseases. To date, 493 MSC-based clinical trials, either complete or ongoing, appear in the database of the US National Institutes of Health. In the present article, we provide a comprehensive review of MSC-based clinical trials conducted worldwide that scrutinizes biological properties of MSCs, elucidates recent clinical findings and clinical trial phases of investigation, highlights therapeutic effects of MSCs, and identifies principal criticisms of the use of these cells. In particular, we analyze clinical trials using MSCs for representative diseases, including hematological disease, graft-versus-host disease, organ transplantation, diabetes, inflammatory diseases, and diseases in the liver, kidney, and lung, as well as cardiovascular, bone and cartilage, neurological, and autoimmune diseases.
Yazarların özeti; kaynağından alınmıştır. Cell Transplantation, 2016 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Genetik (Tıp)
GeneticsMedicine